Dietary Supplement "Gepaktiv"
Fatty Liver, Nonalcoholic
Phenomen PharmaN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Fatty Liver, Nonalcoholic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
S-Adenosyl-L-Methionine Cedars-Sinai Medical Center | Phase 3 | BB |
htd1801 HighTide Biopharma Pty Ltd | Phase 2 | B |
VUPANORSEN Akcea Therapeutics | Phase 2 | B |
met409 active Metacrine, Inc. | Phase 2 | CCC |
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Sadat City University | Phase 1/2 | CCC |
azd7503 AstraZeneca | Phase 1 | CC |
PITAVASTATIN Massachusetts General Hospital | N/A | D |
Same molecule, other indications
Dietary Supplement "Gepaktiv" is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →